Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by NBW Capital LLC

NBW Capital LLC lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 72.2% in the fourth quarter, Holdings Channel reports. The firm owned 19,432 shares of the pharmaceutical company’s stock after purchasing an additional 8,145 shares during the period. Vertex Pharmaceuticals makes up about 1.7% of NBW Capital LLC’s investment portfolio, making the stock its 17th biggest position. NBW Capital LLC’s holdings in Vertex Pharmaceuticals were worth $7,907,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. LSV Asset Management raised its stake in shares of Vertex Pharmaceuticals by 206.3% in the 1st quarter. LSV Asset Management now owns 4,751 shares of the pharmaceutical company’s stock valued at $1,240,000 after acquiring an additional 3,200 shares during the period. Synovus Financial Corp raised its position in Vertex Pharmaceuticals by 9.6% in the first quarter. Synovus Financial Corp now owns 6,737 shares of the pharmaceutical company’s stock valued at $1,759,000 after purchasing an additional 590 shares during the period. Cibc World Market Inc. lifted its stake in shares of Vertex Pharmaceuticals by 69.4% during the first quarter. Cibc World Market Inc. now owns 6,622 shares of the pharmaceutical company’s stock worth $1,728,000 after purchasing an additional 2,713 shares in the last quarter. Sei Investments Co. raised its holdings in shares of Vertex Pharmaceuticals by 28.4% during the 1st quarter. Sei Investments Co. now owns 44,090 shares of the pharmaceutical company’s stock valued at $11,756,000 after buying an additional 9,761 shares during the period. Finally, Cetera Investment Advisers lifted its position in Vertex Pharmaceuticals by 4.0% during the 1st quarter. Cetera Investment Advisers now owns 14,114 shares of the pharmaceutical company’s stock worth $3,683,000 after acquiring an additional 544 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX traded up $0.50 during trading hours on Thursday, reaching $393.60. 415,717 shares of the company’s stock traded hands, compared to its average volume of 1,237,748. The firm has a market capitalization of $101.73 billion, a price-to-earnings ratio of 28.30, a P/E/G ratio of 1.84 and a beta of 0.35. The business’s fifty day simple moving average is $414.76 and its two-hundred day simple moving average is $396.76. Vertex Pharmaceuticals Incorporated has a twelve month low of $316.43 and a twelve month high of $448.40. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.99 and a quick ratio of 3.78.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, topping analysts’ consensus estimates of $3.85 by $0.35. The company had revenue of $2.52 billion during the quarter, compared to analyst estimates of $2.50 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. During the same period in the prior year, the business posted $3.33 EPS. Analysts predict that Vertex Pharmaceuticals Incorporated will post 15.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

VRTX has been the subject of several recent research reports. Maxim Group downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Robert W. Baird lowered Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 price objective for the company. in a research note on Wednesday, January 31st. UBS Group dropped their price objective on Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating on the stock in a report on Wednesday. Truist Financial increased their target price on Vertex Pharmaceuticals from $456.00 to $508.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Finally, Wells Fargo & Company upped their price target on shares of Vertex Pharmaceuticals from $500.00 to $540.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $429.45.

Insider Transactions at Vertex Pharmaceuticals

In related news, COO Stuart A. Arbuckle sold 4,295 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,804,930.80. Following the sale, the chief operating officer now directly owns 75,718 shares in the company, valued at approximately $31,819,732.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Ourania Tatsis sold 354 shares of Vertex Pharmaceuticals stock in a transaction on Monday, February 26th. The stock was sold at an average price of $425.70, for a total transaction of $150,697.80. Following the transaction, the executive vice president now owns 55,804 shares in the company, valued at $23,755,762.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Stuart A. Arbuckle sold 4,295 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,804,930.80. Following the transaction, the chief operating officer now directly owns 75,718 shares in the company, valued at approximately $31,819,732.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 12,381 shares of company stock valued at $5,203,249. Corporate insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.